Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04549428Phase 2Terminated

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

Role: collaborator

NCT04510766Recruiting

Tumor Molecular Profiling in Early Phase Clinical Trials

Role: collaborator

NCT04516850Completed

HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients

Role: collaborator

NCT04539431Unknown

Glioma Brain Tumours - E12513 - SensiScreen Glioma

Role: collaborator

NCT04338542Completed

A Retrospective Study Project of Clinico-molecular Characterization in Patients With Metastatic Colorectal Cancer

Role: collaborator

All 5 trials loaded